Long-term risk of congestive heart failure in younger breast cancer survivors: A nationwide study by the SMARTSHIP group
- Authors
- Lee, Jihyoun; Hur, Ho; Lee, Jong Won; Youn, Hyun Jo; Han, Kyungdo; Kim, Nam Won; Jung, So-Youn; Kim, Zisun; Kim, Ku Sang; Lee, Min Hyuk; Han, Se-Hwan; Jung, Sung Hoo; Chung, Il Yong
- Issue Date
- 1-Jan-2020
- Publisher
- John Wiley & Sons Inc.
- Keywords
- adjuvant; adverse effects; breast neoplasms; chemotherapy; heart diseases; survivorship
- Citation
- Cancer, v.126, no.1, pp 181 - 188
- Pages
- 8
- Journal Title
- Cancer
- Volume
- 126
- Number
- 1
- Start Page
- 181
- End Page
- 188
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/3202
- DOI
- 10.1002/cncr.32485
- ISSN
- 0008-543X
1097-0142
- Abstract
- Background There is a controversy about late-onset congestive heart failure (CHF) among breast cancer survivors. This study investigated the incidence rate and risk factors of late-onset CHF more than 2 years after the breast cancer diagnosis. Methods A nationwide, retrospective study was conducted with the National Health Information Database. With 1:3 age- and sex-matched noncancer controls, Cox proportional hazard regression models were used to analyze the incidence and risk factors of late CHF. The cumulative incidence rate of late CHF was evaluated with a Kaplan-Meier analysis and a log-rank test. Results A total of 91,227 cases (286,480 person-years) and 273,681 controls (884,349 person-years) were evaluated between January 2007 and December 2013. The risks of late CHF were higher in cases than controls (hazard ratio [HR], 1.396; 95% confidence interval [CI], 1.268-1.538). Younger survivors (age <= 50 years) showed a higher risk of late CHF than their younger counterparts (HR, 2.903; 95% CI, 2.425-3.474). Although older age was a risk factor for late CHF, older survivors (age >= 66 years) showed no difference in the risk of late CHF in comparison with their counterparts (HR, 0.906; 95% CI, 0.757-1.084). Anthracyclines and taxanes were risk factors for late CHF, although trastuzumab, radiation, and endocrine therapy were not. Conclusions Young breast cancer survivors have a greater risk of late CHF than the young population without cancer. More attention should be paid to young breast cancer survivors who receive taxane- or anthracycline-based regimens over the long term.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of General Surgery > 1. Journal Articles
- College of Medicine > Department of General Surgery > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/3202)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.